which one is better arna or vvus?? you really want to waste time on a comparison of nwbo and imuc?
If people know what they're doing and stay informed on catalysts and whats happening fundamentally with either stock they can make money off both. But this "my stock is better than your stock" is sooooooo retail.
Its a waste of time, they always end up slashing the payout anyway. I'd rather be a company that pays 3-4% that has a multi year history of increasing the payout and a well know company. Learned my lesson with the reits.
Since not all of the IMUC shareholders have medical degrees or are slick biotech investors it’s the responsibility of the CEO and management to communicate to their shareholders and to people interested, those hard to understand ideas, techniques and anything people have questions/concerns.
If you listen to the conference calls, the analysts that professionally cover this stock do not know all the ins and out of the FDA manufacturing standards, the FDA trial processes, EU regulatory processes, business accounting practices and every other little tidbit concerning IMUC but they ask the questions to get an understanding of what’s going on. And again, management is expected to have a clue or if they draw a blank then are professionally expected to give their best answer and/or say “I’m not sure, but I’ll find out and work out a way to communicate the answer back to you in a timely manner”. So don’t feel you’re at a loss or not able to do this or that when it comes to your investments, because there are resources, you just have to put in the time.
Just be leery of those promoters especially those at Seeking Alpha and question peoples ideas.
If I didn’t have a position or was just starting a position where IMUC shares are in this 2.50-2.75 range, I would buy a small portion of IMUC- so psychologically I can be part of whatever happens and say I didn’t miss out because I know that’s how people think and if things don’t work out, I just chalk it up as a loss and move on. If the results are good, then wait for a selloff because everyone is waiting for the results then pick my spots here and there buying on the dips slowly over the following weeks finally filling out the whole position.
And by the way, I don’t think you need to necessarily look at journals, the point was to find out as much as you can about the investment, whether listening to conference calls, questioning people’s ideas, question your source of information and most importantly: actively trying to figure out what’s going on with your money.
Look at the big winners the last year or so, ACAD or CLDX. The results came, they spiked but came back down after results and gradually went up to over to $20 over a few months to a year. You didn’t just wake up and have a $1 or $4.50 stock run all the way to over $20 in a single night from results. Look at the historical prices of these stocks and see what I’m talking about.
And the most important aspect of this exercise is, just because you didn’t enjoy the rise up to the trial results or deal with the question of whether the results would be good exposing yourself to risk, it still wasn’t too late and was actually the best time to get into stocks after results!! The ship hadn’t left the dock after the results were released with ACAD or CLDX, the gangplank was still lowered with a greeter and a porter to help you with your bags but a lot of people said “I didn’t get involved early and I missed it” but that (crossing arms and signaling no no no lolol) was the wrong thinking, totally wrong!!! That was the best time to get into those stocks concerning one’s risk to reward return..
Anyway, the promoters are setting people up for a fall; the people that are not even considering the possibilities of something going wrong are reckless. As I made the point earlier, these trials aren’t 100% set in stone no matter how favorable the prior results are.
What irritated me with that Springer fellow in that article was he just ignored the possibility of some unknown coming up and just went off that ph1 saying “this is the best opportunity or risk to reward or some nonsense”. And how many ph1s have we seen give good results but do not meet expectations down the line in clinical trials? Or how about the drug that panned out during the trials but for some reason we find out post FDA approval the drug isn’t safe like with AFFY’s Omontys? That’s why we do all the trials because its not guaranteed that earlier trials produce the same stellar results under more stringent guidance and even when things work out there’s always an “unknown” as with Omontys .
I just thought it was reckless to tell people this was a winner and not even consider a problem because “How Do You Fake 7 Of 16 Five-Year Glioblastoma Survivors?” lolol
And I don’t even agree with that guy’s risk/reward thinking anyway. We’ve seen stocks that made awesome runs the last year or so and they have proven the easy money comes after the results are released. There is the price spike (if the results are good) followed by a selloff then a price range is established, then it stays in that range for awhile and my guess is a month or 2 after the results are released the big investors have been given enough time to think over establishing a position or increasing the position and the stocks take off to the sky over the following months. Its that 1 month after the results that’s the real easy money is, not the results.
Back to chinamannyc2003, listen to what you’re saying, trying to guess the percentage of success of a trial. You’re exposing yourself to more risk than reward, that’s not the way to go. The promoters are making people focus on the trial results and telling you gotta have it or you’re going to miss out, that’s the backwards way of thinking. You should be thinking about right after the results come out, that’s where the easy money is.
I’m in the same boat you’re in concerning IMUC’s upcoming trial, sorry, lol.
You want a simple answer to a complex issue and even if I gave an answer it would be an unreliable one because it would be based on a small amount of data and although I question ideas, giving the impression I am negative on IMUC sometimes, in reality, I am favorably biased toward IMUC. I just like to have an understanding of what’s going on and question anything when it comes to my investments in hopes of avoiding a disaster.
But here, I think you’re asking the wrong question anyway, lolo, but perhaps not, depending on your risk tolerance. Instead of asking about the test results, have you considered what the best risk/reward proposition might be? I’ll come back to this in a second.
I finally read “How Do You Fake 7 Of 16 Five-Year Glioblastoma Survivors?” by Springer and I have not paid attention to this person because I don’t post on Seeking Alpha a lot and I am not familiar with his writings but people have mentioned him a few times in the last few weeks on this board so I sat and read it.
I wasn’t happy lololololl, and he really didn’t add much to the IMUC conversation on that piece because I could have gotten nearly the same info watching that 2012 CNN video”Vaccine offers hope for cancer patients” on ict107 where the patients are doing really well a few years out from being treated for GBM but again it boils do to the reliability of such a small sample in a Phase 1 trial.
if you bought shares and thought you were going to avoid the price swing, you are very very foolish.
My problem with that particular posting of yours was that you can't go off a ph1 study as a sole investing thesis.
The other problem I have and its not related to you is that the promoters keep going back to that ph 1 study and many retail investors do understand the limits and reliability of a ph1 study. Most of them do not have a firm understanding of basic DC technology.
What I am saying here is that these investors are reading promotion material looking at these fantastic results without understanding the flaws and limits of a ph1 study and get suckered in.
That website I provided was a nonbiased EDU video produced by a leading researcher, it would help someone gain a basic idea of what all these DC companies are trying to do. So it could help people get into the conversation with not only IMUC but other companies working in the DC space.
I read your comments of “what does this have to do with IMUC?” and I scratched my head and moved on.
But telling people to go off that ph1 study without telling people of the drawbacks of such a study is irresponsible and this is another issue I have with promoters.
Stay away from the promoters, the Seeking Alpha promoters and bloggers. Anyone that isn’t willing to consider the other side of a trade whether bull or bear isn’t giving the whole picture.
TSLA is one of those momentum stocks like Apple, CMG, amazon and netflix.
A lot of people wondered how low it could go when the momentum was taken away, so we'll find out.
but the trend with these other stock is they get killed then rally hard. Netflix, we know about. Amazon reported I think it was 2 or 3 quarters ago and went down over 25% in the after hours but rebounded, CMG got wrecked a few quarters after reporting but look at it now, and everyone knows the AAPL story.
These companies are like biotech, big ranges so you need to be able to tolerate the swings while keeping an eye on the longterm picture.
I would spend more time trying to figure out what the company has to offer rather than what the stock price is doing so you can figure out the pros and cons of the company and evaluate it. The hype and news stories on the networks are practically worthless. And if you don’t understand the car industry I don’t see why you even would get involved in it. Too much retail hype either way and not enough time spent learning about a sector and a company is bad. But that’s the world we live in, trade, trade trade zippo on the research but lets ride the trend. Lol.
A lot of shareholders will not have the experience or expertise to deal with the swings so it might be best to search for a well known etf that has a high percentage of Tesla in it with high liquidity and call it a day. A website called “ETF Channel” has a large listing of such etfs but I would look at other places for info.
I don't know enough about TSLA and I don't have an interest in it, but I don’t think the story is over because traders decide to sell shares. I would just watch to see how low it could go before finding solid support range.
but really, who's paying for attendance for all those dermatological conferences? the hotels, the meals, the flights? How many major dermatological conferences are there in a year?
Nevermind this is just another example that the kiddy traders are getting back into imuc again and want attention and time.
Time for another little vacation here. I've said all i can say and done all i can do, its just a matter of the results and you people not getting greedy by heavily loading up a position and worrying about it.
the expenses were addressed 2 calls ago by Coradini and we will see if management can hack into the expenses here soon.
I'm thinking those termination fees on the last call weren't for nothing, but we'll see.
Management needs to show direction and realistic expectations. they need to focus on their customers -the dermatologists and win their support, the conferences and targeting the general public hasn't worked, they need another approach.
but to answer your question, i don't think its going to be $6M a quarter for long but how low and will it give them enough time to win over the doctors? i don't know.
this board has addressed Yu's options/sells in the past, i suggest you type Yu in the message board search and read what people posted awhile back instead of "going down that road" again, and again and again, its the same thing.
This is an extremely negative perspective on the company, and I think this is just as bad as having an extremely positive vision of the company, both aren’t productive.
Last quarter was very productive with the board shake up, but now I need to see the year over year revenues numbers continue to increase but the number one issue here is the expenses.
If management can shave expenses down I would be happy Management also has to be more vocal with these expenses and the direction of the company.
lololol I follow this stock on a regular basis and I can't even find anything on what they're spending over $1M R&D expenses a quarter on!!
that shouldn't be an email to Mela IR, this is a medical device company whose management should be putting that info out on a regular basis.
just shows that management still has many flaws.
do research, stay up-to-date on company/sector current events and try to stay ahead of people publishing their opinions. not hard, just means being involved in your stocks.
and who's Jessica Simpson? that name sounds familiar but i really dont remember who that is.
hmmmm nevermind, but i do remember the names of WTW management who tanked shares on their end of the world guidance and how they are working day and night to save the world from the boogeyman.
Hopefully the next quarter is descent and management looks silly with that guidance and we can boot them on the proxy for creating this end of the world hysteria, but ooh someone owns more than 50% of the float, maybe we cant.
going much lower, offering coming, much lower. 50s easy in 3 months. I'm guessing management is talking to someone to do the next offering soon if they haven't already.
So what would you offer shares at 60 cents ? 55 cents? Whatever the price is there will be downward momentum after the offering.
Shares need to pick up steam and they can do this by increasing the year over year revenues to attract growth investors and cut down on the expenses which both Gulfo and Coradini had trouble with.
getting the balance sheet under control should be priority number 1, not talking about revamp projects or making the expenses grow.